新疆中泰化学股份有限公司 关于公司向新疆中泰金晖能源股份有限公司 提供财务资助暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、提供财务资助暨关联交易事项概述 证券代码：002092 证券简称：中泰化学 公告编号：2025-055 债券代码：148437 债券简称：23 新化 K1 1 鉴于公司控股股东新疆中泰（集团）有限责任公司持有中泰金晖 0.44%股份， 上述财务资助事项构成关联交易。根据《深圳证券交易所股票上市规则》等相关 规定，本次提供财务资助构成关联交易，但不构成《上市公司重大资产重组管理 办法》规定的重大资产重组。 二、接受财务资助对象的基本情况 1、基本情况 （一）财务资助金额、期限及用途 新疆中泰化学股份有限公司（以下简称"公司"）持有新疆中泰金晖能源股 份有限公司（以下简称"中泰金晖"）36.0645%股份，为公司控股子公司。中泰 金晖全资子公司新疆中泰金晖科技有限公司（以下简称"金晖科技"）2022 年 投资建设年产 30 万吨 BDO（1,4-丁二醇）项目，为确保中泰金晖正常经营周转 及金晖科技项目顺利建设，公司拟根 ...

新疆中泰化学股份有限公司 关于召开2025年第四次临时股东会通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 根据新疆中泰化学股份有限公司（以下简称"公司"）八届三十一次董事会 提请股东会审议的有关议案，需提交股东会审议并通过。鉴于此，现提请召开股 东会，就本次股东会之有关事项说明如下： 证券代码：002092 证券简称：中泰化学 公告编号：2025-057 债券代码：148437 债券简称：23 新化 K1 一、会议召开基本情况 （一）股东会名称：2025 年第四次临时股东会 （二）会议召集人：公司董事会 （三）本次股东会由公司董事会提议召开，会议的召集程序符合《公司法》、 《深圳证券交易所股票上市规则》等法律、法规、规范性文件及《公司章程》的 规定。 （四）会议时间： 1、现场会议时间为：2025 年 11 月 10 日上午 12:00 2、网络投票时间为：2025 年 11 月 10 日，其中通过深圳证券交易所交易系 统进行网络投票的具体时间为：2025 年 11 月 10 日上午 9:15-9:25，9:30-11:30， 下午 13:00- ...

证券代码：002092 证券简称：中泰化学 公告编号：2025-052 债券代码：148437 债券简称：23 新化 K1 新疆中泰化学股份有限公司 八届三十一次董事会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 新疆中泰化学股份有限公司（以下简称"公司"或"中泰化学"）八届三十一次 董事会会议于2025年10月17日以电话、电子邮件等方式发出会议通知，于2025 年10月23日以通讯表决方式召开。会议应参加表决的董事9名，实际参加表决的 董事9名，会议的召开程序符合《公司法》和《公司章程》的规定。会议就提交 的各项议案形成以下决议： 一、会议以赞成票 9 票，反对票 0 票，弃权票 0 票，审议通过新疆中泰化学 股份有限公司 2025 年第三季度报告； 详 细 内 容 见 2025 年 10 月 24 日 刊 登 在 《 证 券 时 报 》 和 巨 潮 资 讯 网 http://www.cninfo.com.cn上的《新疆中泰化学股份有限公司2025年第三季度报 告》。 二、会议以赞成票 7 票，反对票 0 票，弃权票 0 票，审议通过关于终止实 ...

Core Viewpoint - The company plans to terminate the 2021 restricted stock incentive plan and repurchase the unvested restricted stocks, indicating a strategic shift in its employee incentive approach [1] Summary by Sections Stock Repurchase - The company will repurchase and cancel 14.28 million shares of restricted stock granted to 873 incentive recipients who have not yet had their restrictions lifted [1] - The repurchase price for 20 individuals who were dismissed, transferred, or retired in 2023 is set at 4.65 RMB per share, with the same price applying to the remaining 853 individuals [1] - The total expected repurchase amount is 66.5655 million RMB, funded by the company's own resources [1] Impact on Share Capital - Following the completion of the repurchase and cancellation, the company's total share capital is projected to decrease from 2.59 billion shares to 2.576 billion shares [1]

中泰化学公告，第三季度营收为72.9亿元，同比增长0.26%；净利润为1490.08万元，同比增长 114.18%。前三季度营收为212.46亿元，同比下降5.55%；净利润亏损1.79亿元，同比下降48.51%。 ...

Financial Performance - The company's operating revenue for the third quarter was ¥7,290,453,129.77, an increase of 0.26% year-on-year[5] - Net profit attributable to shareholders was ¥14,900,818.83, representing a significant increase of 114.18% compared to the same period last year[5] - The company reported a decrease in net profit attributable to shareholders after deducting non-recurring gains and losses, amounting to -¥2,181,601.45, a decline of 98.49%[5] - Total operating revenue for the current period was ¥21,245,520,041.34, a decrease of 5.55% from ¥22,493,111,043.98 in the previous period[31] - Net profit for the current period was a loss of ¥253,138,793.74, an improvement from a loss of ¥426,192,132.86 in the previous period[32] - The total comprehensive income for the current period was a loss of ¥260,267,288.50, compared to a loss of ¥440,189,463.49 in the previous period[33] - Basic and diluted earnings per share were both -0.0696, an improvement from -0.1351 in the previous period[33] Cash Flow - The net cash flow from operating activities decreased by 67.15% to ¥1,393,589,180.45 due to a reduction in cash received from operating activities[18] - Cash inflow from operating activities totaled ¥27,192,853,928.79, down from ¥31,832,380,207.62 in the previous period[35] - The net cash flow from operating activities was 1,393,589,180.45, a decrease of 67.2% compared to 4,242,725,760.60 from the previous period[36] - Cash outflows from operating activities totaled 25,799,264,748.34, down from 27,589,654,447.02, indicating a reduction of 6.5%[36] - The net cash flow from investing activities was -2,359,594,268.00, slightly improved from -2,440,506,826.18 in the prior period[36] - Cash inflows from financing activities amounted to 14,013,443,723.22, an increase of 19.3% compared to 11,735,819,003.85[37] - The net cash flow from financing activities was 1,776,309,881.16, a significant recovery from -338,320,617.81 in the previous period[37] - The ending balance of cash and cash equivalents was 2,794,082,282.08, down from 3,574,408,444.35, reflecting a decrease of 21.8%[37] - The company paid 9,085,808,853.42 in debt repayments, which increased from 7,038,487,997.63, representing a rise of 29.1%[37] - The total cash outflows related to financing activities were 12,237,133,842.06, slightly up from 12,074,139,621.66, indicating a 1.4% increase[37] - The company received 10,866,615,440.40 in cash from borrowings, which is a slight increase from 10,679,414,047.74, showing a growth of 1.8%[37] Assets and Liabilities - Total assets at the end of the reporting period were ¥78,309,580,150.14, reflecting a 1.67% increase from the previous year[6] - The total assets as of September 30, 2025, amounted to CNY 78.31 billion, an increase from CNY 77.02 billion at the beginning of the period[26] - Current assets reached CNY 15.91 billion, up from CNY 13.12 billion at the start of the period, indicating a growth of approximately 21.2%[27] - The company's cash and cash equivalents increased to CNY 6.83 billion from CNY 4.77 billion, representing a growth of about 43%[26] - Short-term borrowings slightly increased to CNY 5.37 billion from CNY 5.34 billion, showing a marginal rise[28] - Non-current liabilities rose to CNY 19.13 billion from CNY 15.93 billion, reflecting an increase of approximately 20.5%[28] - The total liabilities as of September 30, 2025, were CNY 50.68 billion, compared to CNY 48.98 billion at the beginning of the period, indicating an increase of about 3.5%[28] - Total equity attributable to shareholders of the parent company was ¥21,585,169,660.71, a decrease from ¥21,783,601,095.48 in the previous period[28] Operational Highlights - The company experienced a 36.83% increase in receivables financing, totaling ¥1,056,277,872.65, attributed to an increase in bank acceptance bills[13] - The company’s prepayments increased by 55.21% to ¥891,794,031.34, driven by an increase in advance payments for pulp[13] - The company recorded a 139.82% increase in income tax expenses, amounting to ¥130,152,784.95, due to higher profit levels and an expanded consolidation scope[16] - In Q3 2025, the company produced 1.8758 million tons of PVC resin, 1.3074 million tons of caustic soda, 407,400 tons of viscose fiber, and 228,700 tons of viscose yarn[23] - The company emphasized a market-oriented approach, focusing on differentiated downstream products to enhance market competitiveness[23] - The company aims to strengthen innovation and market collaboration to improve production efficiency and meet market demands[23] Audit and Compliance - The company did not undergo an audit for the third quarter financial report[38]

证券代码：002092 证券简称：中泰化学 公告编号：2025-054 债券代码：148437 债券简称：23 新化 K1 关于终止实施 2021 年限制性股票激励计划 并回购注销限制性股票的公告 新疆中泰化学股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1、2021 年 11 月 12 日，公司七届二十九次董事会、七届二十七次监事会审 议通过了《新疆中泰化学股份有限公司 2021 年限制性股票激励计划（草案）》及 其摘要的议案、关于《新疆中泰化学股份有限公司 2021 年限制性股票激励计划 管理办法》的议案、关于《新疆中泰化学股份有限公司 2021 年限制性股票激励 计划业绩考核办法》的议案。公司独立董事对本次激励计划发表了同意的独立意 见，监事会发表了核查意见。 2、2021 年 12 月 15 日，公司七届三十一次董事会、七届二十八次监事会审 议通过了关于《新疆中泰化学股份有限公司 2021 年限制性股票激励计划（草案 修订稿）》及其摘要的议案、关于《新疆中泰化学股份有限公司 2021 年限制性股 票激励计划管理办法（修订稿）》的议案、关 ...

关于新疆中泰化学股份有限公司 终止实施 2021 年限制性股票激励计划并 回购注销限制性股票相关事项 之 法 律 意 见 书 中国·上海 SHANGHAI·CHINA 上海市浦东东方路 710 号 汤臣国际金融大厦六楼 邮 编 : 200122 电 话 : 86-21-58204822 传 真 : 86-21-58203032 6/F Tomson Financial Building 710 Dong Fang Road Shanghai 200122 P. R. China Tel. : 86-21-58204822 Fax : 86-21-58203032 关于新疆中泰化学股份有限公司终止实施 2021 年限制性股票激励计划并回购注销限制性股票相关事项之 法 律 意 见 书 致：新疆中泰化学股份有限公司 上海市浦栋律师事务所（以下简称"本所"）接受新疆中泰化学股份有限公 司（以下简称"中泰化学"或"公司"）的委托，担任公司 2021 年限制性股票 激励计划（以下简称"激励计划"或"本次激励计划"）相关事宜的专项法律顾 问。 浦 栋 律 师 事 务 所 PU DONG LAW OFFICE 本所根据《中华 ...

二〇二五年十月二十一日 1 董事会薪酬与考核委员会关于终止实施 2021 年限制性股票 激励计划并回购注销限制性股票事项的审核意见 新疆中泰化学股份有限公司 董事会薪酬与考核委员会 新疆中泰化学股份有限公司 新疆中泰化学股份有限公司（以下简称"公司"）依照《公司法》和《公司 章程》的有关规定于2025年10月21日召开了2025年第二次薪酬与考核委员会。经 与会成员认真审议，会议全票表决通过《关于终止实施2021年限制性股票激励计 划并回购注销限制性股票的议案》。公司董事会薪酬与考核委员会对上述事项发 表如下审查意见： 经核查，公司本次终止实施 2021 年限制性股票激励计划并回购注销限制性 股票的行为符合《上市公司股权激励管理办法》及《激励计划》等相关规定，本 次终止激励计划暨回购注销事项不会对公司的财务状况及股东权益产生重大影 响，也不存在损害公司及全体股东利益的情形。薪酬与考核委员会同意本次终止 实施 2021 年限制性股票激励计划并回购注销限制性股票事项，并同意将该事项 提交至公司董事会审议。 ...

Market Overview - As of 14:00, the Shanghai Composite Index is at 3859.80 points, with an increase of 0.52% [1] - The total trading volume of A-shares today is 1,431.28 billion yuan [1] Technical Analysis - A total of 84 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - The stocks with the largest distance between their 5-day and 10-day moving averages include: - Yunnan Zhenye: 5-day MA is -2.45% below the 10-day MA [1] - Qiangli New Materials: 5-day MA is -2.22% below the 10-day MA [1] - Feirongda: 5-day MA is -2.14% below the 10-day MA [1] Individual Stock Performance - Yunnan Zhenye (002428): Today's change is -0.93%, with a 5-day MA of 27.71 yuan and a 10-day MA of 28.41 yuan [1] - Qiangli New Materials (300429): Today's change is +0.53%, with a 5-day MA of 13.95 yuan and a 10-day MA of 14.26 yuan [1] - Feirongda (300602): Today's change is +1.03%, with a 5-day MA of 33.00 yuan and a 10-day MA of 33.72 yuan [1] - Other notable stocks include: - Warner Pharmaceuticals (688799): Today's change is +0.43%, with a 5-day MA of 55.41 yuan [1] - Blue Ying Equipment (300293): Today's change is +0.34%, with a 5-day MA of 24.48 yuan [1] Additional Stock Data - The following stocks also show a downward trend in their 5-day moving averages compared to their 10-day moving averages: - Nanya New Materials (688519): -0.90% change, 5-day MA of 74.18 yuan [1] - Aerospace Morning Light (600501): -2.84% change, 5-day MA of 23.60 yuan [1] - Haichen Pharmaceutical (300584): +1.92% change, 5-day MA of 57.39 yuan [1]